Healthcare stock jumps 7% after it reports 26% YoY revenue growth in Q3

Synopsis: Metropolis Healthcare has shared a business update for the quarter ended December 31, 2025, outlining how the company performed during the period. The update highlights demand trends, growth across key segments, and progress in integrating its acquired businesses, and a strong consolidated revenue growth of around 26% year-on-year in Q3FY26.

The shares of this healthcare stock majorly engaged in  providing pathology and related healthcare services offering a wide range of clinical tests and profiles which includes advanced diagnostics for cancer, neurological disorders, infectious diseases, and genetic abnormalities, jumped over 6 percent after its Q3 business update, with consolidated revenue rising around 26 percent year-on-year, driven by healthy growth across verticals.

With the market capitalization of  Rs. 10,642 Crores, the shares of Metropolis Healthcare Ltd, has touched an intraday high of Rs. 2060 per share, rising nearly  6.5 percent from previous day closing of Rs. 1933 per share. 

Why the stock jumped over 8 percent: 

Metropolis Healthcare informed the stock exchanges that it delivered a strong consolidated revenue growth of around 26% year-on-year in Q3FY26, driven by steady demand for preventive health check-ups under its TruHealth platform and a sharp rise in specialty testing volumes across both B2C and B2B channels.

The performance includes contributions from acquired entities such as Core Diagnostics, Scientific Pathology in Agra, Dr. Ahuja’s Pathology & Imaging Center (DAPIC) in Dehradun, and Ambika Pathology Laboratory in Kolhapur.

 The company said the integration of these acquisitions is progressing well, helping improve operational efficiency and operating leverage, with Core Diagnostics margins remaining similar to Q2 levels, while DAPIC, Scientific, and Ambika continued to outperform the company’s average margins. During the quarter, the TruHealth wellness segment grew by around 35% year-on-year, while the specialty segment recorded growth of about 33%. 

On the customer mix, B2C revenues increased by around 18% year-on-year, while B2B revenues rose sharply by about 37%, supported by higher wallet share from customers, especially in the specialty segment, and a higher contribution from Core Diagnostics. 

On a standalone basis, revenues grew by approximately 15% year-on-year, mainly due to higher patient and test volumes, along with a better product mix and improved realizations. The TruHealth wellness segment and specialty segment on a standalone basis grew by around 23% and 16%, respectively, while B2C and B2B revenues increased by about 14% and 16%, respectively. 

Despite Q3 being a seasonally weaker quarter for the diagnostics industry, the company reported a year-on-year expansion in EBITDA margins, highlighting the resilience of its operations and the strength of operating leverage in its business model. 

Also read: Marico shares at 52-week high after robust Q3 business update; What’s next?

About the Company and Financials: 

Metropolis healthcare ltd. is majorly engaged in  providing pathology and related healthcare services offering a wide range of clinical tests and profiles which includes advanced diagnostics for cancer, neurological disorders, infectious diseases, and genetic abnormalities. The company has a robust service network of over 4,600 and over 4,000 tests and profiles. The company is into both B2B and B2C contributing 59 percent and 41 percent respectively  

Year on Year analysis:Revenue from operations has increased from Rs. 350 Crores to Rs. 429 Crore, up 22.5 percent. Operating profit has increased from Rs. 90 Crores to Rs. 108 Crores, up 20 percent and net profit has increased from Rs. 47 Crores to Rs. 53 Crores, up 12.7 percent. 

Quarter on Quarter analysis: Revenue from operations has increased from Rs. 386 Crores to Rs. 429 Crores, up 11 percent. Operating profit has increased from Rs. 90 Crores to Rs. 108 Crores, up 20 percent and net profit has increased from Rs. 45 Crores to Rs. 53 Crores, up 17.7 percent  

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Healthcare stock jumps 7% after it reports 26% YoY revenue growth in Q3 appeared first on Trade Brains.